SCHEMBL112264

SCHEMBL112264

CC(C)COC(=O)N1CCNCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.44
KIT P10721 1/20 0.41
MEN1 O00255 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
CA2 P00918 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA9 Q16790 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM3 P20309 1/20 0.39
CHKA P35790 1/20 0.38
TSHR P16473 3/20 0.38
HRH2 P25021 1/20 0.38
HRH1 P35367 1/20 0.38
P2RX4 Q99571 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA4 P43681 1/20 0.37
CHRNB3 Q05901 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1873610 0.93 RAB9A (0.43) RAB9AKITMEN1HPGDKMT2A
SCHEMBL2730686 0.86 CA2 (0.37) CA2CA12CA1CA9CHRM5
SCHEMBL28938071 0.84 TSHR (0.39) MEN1KMT2ACA2CA12CA1
SCHEMBL28722507 0.84 TSHR (0.39) MEN1KMT2ACA2CA12CA1
SCHEMBL30066494 0.83 GAA (0.38) RAB9ACA2CA12CA1CA9
SCHEMBL5407237 0.82 MEN1 (0.52) RAB9AKITMEN1HPGDKMT2A
SCHEMBL12233216 0.82 RAB9A (0.51) RAB9AKITMEN1HPGDKMT2A
SCHEMBL24793049 0.82 CHRNB2 (0.40) CA2CA12CA1CA9CHRM5
SCHEMBL26824211 0.82 CA2 (0.37) RAB9AMEN1HPGDKMT2ACA2
SCHEMBL5217684 0.81 RAB9A (0.43) RAB9AKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011094890-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS ARGUSINA INC. (US) 2011-08-11 WO claimed
US-20070232559-A1 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2007-10-04 US claimed
US-20250354195-A1 METHOD OF SCREENING UNIV DUNDEE (GB) 2025-11-20 US disclosed
WO-2024059665-A1 DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-03-21 WO disclosed
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 US disclosed
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 US disclosed
WO-2023122600-A1 PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS CORCEPT THERAPEUTICS INCORPORATED (US) 2023-06-29 WO disclosed
WO-2022198196-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2022-09-22 WO disclosed
CN-111848591-B HDAC inhibitors and methods of making and using the same 成都先导药物开发股份有限公司 2022-03-18 CN disclosed
WO-2020150372-A1 ANTIMICROBIAL COMPOUNDS AND METHODS CURZA GLOBAL, LLC (US) 2020-07-23 WO disclosed
CN-106458985-B 6-heteroaryloxy-and 6-aryloxy-quinoline-2-carboxamides and their use 艾伯维公司 2019-05-03 CN disclosed
EP-0123977-A1 Substituted piperazin-1-yl-acetic-acid amides, process for their preparation and their use CASSELLA Aktiengesellschaft (DE) 1984-11-07 EP disclosed
EP-0082023-A2 Thienopyrimidine derivatives, their preparation and their medical use SANKYO COMPANY LIMITED (JP) 1983-06-22 EP disclosed
US-4352928-A ANTIINFLAMMATORY, HYPOGLYCEMIC, ANTICOAGULANT, ANOREXIGENIC, SEROTONIN EFFEC MITSUBISHI YUKA PHARMACEUTICAL CO., LTD. (JP) 1982-10-05 US disclosed
EP-0022481-A1 5,6-Alkylenepyrimidine derivatives, processes for preparing the same and pharmaceutical compositions Mitsubishi Yuka Pharmaceutical Co., Ltd. (JP) 1981-01-21 EP disclosed
US-4176191-A HYPOTENSIVE AGENTS ABBOTT LABORATORIES (US) 1979-11-27 US disclosed
US-4148895-A HYPOTENSIVE, ANTIARRHYMIA AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1979-04-10 US disclosed
US-4145422-A HYPOTENSIVES ABBOTT LABORATORIES (US) 1979-03-20 US disclosed
US-4093726-A HYPOTENSIVE AGENTS ABBOTT LABORATORIES (US) 1978-06-06 US disclosed
US-3933802-A New sulphamoylbenzoic acid amides CIBA-GEIGY CORPORATION (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS2, GYS1, PYGL RAB9A 2526/4885KIT 4274/4885MEN1 1095/4885
US-20070232559-A1 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF ADORA2A, ADORA3, ADORA1 RAB9A 1308/4885KIT 1812/4885MEN1 2054/4885
US-20250354195-A1 METHOD OF SCREENING PAICS, COASY, ABCG2 RAB9A 1916/4885KIT 14/4885MEN1 793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.